<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946607</url>
  </required_header>
  <id_info>
    <org_study_id>09/H0605/60</org_study_id>
    <nct_id>NCT01946607</nct_id>
  </id_info>
  <brief_title>Antidepressants, Emotions and Personality</brief_title>
  <official_title>Antidepressants, Emotions and Personality: Comparing the Neuropsychological Effects of the Antidepressant Citalopram in Healthy Volunteers With High and Low Neuroticism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Council Cognition and Brain Sciences Unit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroticism is a personality trait described as an enduring tendency to experience negative
      emotional states and to respond poorly to environmental stress. It has been shown that high
      neuroticism can predispose, amongst other factors, to the development of depressive episodes.
      Recent studies suggest that subjects with high neuroticism have a different response to
      stimuli with an emotional content, showing both decreased processing of positive or increased
      processing of negative emotionally salient cues. These differences in cognitive processing of
      emotional stimuli are believed to underpin the psychological characteristics that link high
      neuroticism with a higher risk for depression.

      Preliminary data also indicate that modulation of serotonin function by antidepressant
      treatment in healthy volunteers with high neuroticism traits could modify the brain activity
      associated with the processing of emotional stimuli that is dysfunctional in this vulnerable
      population.

      The aim of this research is to investigate further whether modulation of serotonin function
      via administration of serotonergic antidepressants (SSRIs) can revert the dysfunctional
      emotion processing that characterises subjects with the personality trait of high
      neuroticism.

      In particular we hypothesise that SSRI administration will modify the abnormal patterns in
      attention, physiological reactivity and regulation of emotional stimuli present in healthy
      individuals with the vulnerable personality trait of high neuroticism.

      Carrying out this research on healthy volunteers will enable us to understand if modulating
      serotonin function by antidepressant administration has an effect not only on mood symptoms -
      as is evident in depressed patients - but also on the predisposing psychological and
      cognitive processes that sustain the depressed mood, such as the response to emotional
      stimuli. We will also be able to verify if this effect is shown early treatment and prior to
      any subjective changes in mood. This will be done by administering seven days of either the
      antidepressant citalopram or placebo to subjects with high neuroticism scores and then
      comparing them on a series of computer based psychological tests measuring various aspects of
      how emotionally salient stimuli are processed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty healthy volunteers with high scores on the Eysenck Personality Questionnaire
      Neuroticism scale will be recruited from the general population using posters and advertising
      in local newspapers and on internet. All advertisement will direct volunteers to a specific
      website (http://weblearn.ox.ac.uk/site/users/psyc0390/public/) (hosted in the Weblearn area
      of the University of Oxford) that will report the study Information Sheet. People clicking on
      the &quot;I agree to participate&quot; link will then be able to leave their contact details and fill
      in a shortened version of the Eysenck Personality Questionnaire. Questionnaire results will
      be anonymous and only the researcher will access the data and the correspondent contact
      details. Thus, only volunteers consenting to participate to the full study will be screened
      for neuroticism scores and only suitable ones will be contacted for the screening visit.

      Participants will be requested to come to the Department of Psychiatry of the University of
      Oxford for an initial screening assessment including basic medical examination and structured
      psychiatric interview. On that occasion they will also be asked to complete a number of
      questionnaires such as Beck Depression Inventory, Dysfunctional Attitudes Scale, State-Trait
      Anxiety Inventory, Eysenck Personality Questionnaire, Parental Bonding Instruments and Life
      Events Rating Scale.

      Volunteers will be randomized to receive citalopram or placebo in a double blind between
      groups design for 7 days. They will receive the treatment capsules to take home and will be
      instructed to take the capsule every morning after breakfast around 8 am. Subjective mood
      will be assessed on each day of treatment using the Befindlichskeit scale of mood and energy,
      the State Anxiety Inventory and Visual Analogue Scales. Side-effects will be registered every
      day using a specific side-effects report sheet.

      On the day before starting the treatment (Day 0) and on the last day of treatment (Day 7)
      participants will be asked to collect saliva sample to measure cortisol levels. Collection of
      samples will be performed by participants in their own home and is non-invasive. Participants
      will be provided with appropriate collection vessels containing a cotton swab. They will be
      asked to roll this swab around in their mouths for a minute after waking and take 4 further
      samples at 15 minute intervals, each on a separate cotton swab. The cotton swabs will be put
      back in the collection vessel and participants will be asked to store their saliva samples in
      the freezer and bring them back to the researcher on the day of testing.

      Participants will be given the mobile phone number of the Principal Investigator (PI) so that
      they can immediately get in contact if they have any concerns when taking the drug. In
      addition, the researcher will contact participants within the first few days to ensure that
      they are not experiencing any side effects. Participants experiencing more than mild
      transient side effects will be advised to stop taking the drugs and will be withdrawn from
      the study.

      On the last day of treatment (Day 7), participants will come to the Department of
      Experimental Psychology of the University of Oxford around 2 pm, which corresponds to time
      when the drug reaches its peak in blood levels. They will be asked to complete again part of
      the questionnaires administered on the first day and then they will complete a battery of
      neuropsychological tests including attentional tests, facial expression recognition tests and
      emotional regulation tests, as used in our previous studies. During the emotional regulation
      test an ECG will also be recorded. The testing session will last approximately 3 hours.

      If the participant agreed, we would then also collect a blood sample to identify a particular
      gene (the serotonin transporter polymorphism) that may influence some of those measures and
      to assess the citalopram drug level in order to check that the treatment was taken.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye gaze fixations over the region of the eyes and whole face region of facial expressions during a gender discrimination task of emotional facial expressions</measure>
    <time_frame>Day 7 of treatment administration</time_frame>
    <description>Fixations were defined as a set of eye positions within a defined area for a selected amount of time. We adopted the default values defining a fixation to be within a 0.30 x 0.30 degree box for 100 ms and calculating fixations using a velocity/distance algorithm. In the calculation, subjects' eyes are allowed to drift during fixation as long as the amount of drift is less than this area per 100 ms. We calculated the number of fixations present within the Region of Interest (ROI) of the eyes of the facial expressions used as stimuli in the task.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scanpath length over the eye region and whole face region of facial expressions during a gender discrimination task of emotional facial expressions</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Scanpath length refers to the summed distances travelled by the eye during scanning, and is typically measured in degrees of visual angle (expressed in pixels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scanning time over the eyes region and whole face of facial expressions during a gender discrimination task of emotional facial expressions</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Scanning time refers to the time spent by the eye travelling over the stimuli, and is calculated in ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gaze maintenance over the eyes region and whole face of facial expressions during a gender discrimination task of emotional facial expressions</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>The gaze maintenance calculation indicated whether gaze was or was not maintained in the selected ROI (eyes, whole face) for the entire duration of each trial (500ms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy and reaction time of emotional facial expressions recognition during a facial expressions recognition task</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Correct labelling of emotional facial expressions presented on a screen for 500ms at intensities varying between 10% and 100%: correct responses and misclassifications are recorded, and accuracy is measured calculating the average expression intensity threshold needed to correctly identify each emotion. Reaction times to correctly label facial expressions is recorded in ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall and recognition scores and reaction times during a memory task for emotionally valenced self-descriptors</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Number of correctly recalled, false alarms and number of recognised positive and negative self-descriptors, and reaction time in ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye-blink reflex magnitudes in response to pleasant, unpleasant and neutral pictures during an emotion potentiated startle task</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Eye-blink reflex magnitudes in microvolts were calculated by subtracting the amount of integrated EMG at reflex onset from the first peak amplitude of integrated EMG between 20 and 120 ms following probe onset. Trials with no traceable eye-blink reflex were assigned a magnitude of zero and included in the analysis. Eye-blink reflexes with excessive noise during the 20-ms, pre-startle baseline period were excluded. This task provides a measure of the relative acoustic startle response during unpleasant, pleasant and neutral pictorial stimuli presentation. Eye-blink reflex magnitudes were z-transformed within subjects to allow comparison between these different conditions and minimise inter-subject variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Frequency Heart Rate Variability (HF-HRV) during an emotion regulation task of unpleasant pictures</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>HF-HRV for each condition in the task (i.e. while passively viewing unpleasant pictures, &quot;maintain condition&quot;, and while down-regulating the emotion elicited by unpleasant pictures, &quot;suppress condition&quot;) and for 1 min &quot;pre-task&quot; period was calculated by integrating the spectral power across the bandwidth 0.15-0.4 Hz; normalised HF and LF values (HFn and LFn) were also calculated by dividing the HF-HRV and LF-HRV by the total power in the range above 0.04 Hz (&quot;normalisation power&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affect ratings during an emotion regulation task of unpleasant pictures</measure>
    <time_frame>Day 7 of treatment</time_frame>
    <description>Rating of negative affect on a 5-point Likert scale after passive viewing (&quot;maintain emotion&quot; condition) or active down-regulation of the emotion elicited by unpleasant pictures (&quot;suppress emotion&quot; condition).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in waking salivary cortisol levels</measure>
    <time_frame>Change from baseline (day 0) to day 7 of treatment</time_frame>
    <description>Change in levels of waking salivary cortisol from baseline pre-treatment to after 7 days of treatment administration</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Antidepressive Agents, Second-Generation</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Male or Female, aged 18 - 50 years

          -  Eysenck Personality Questionnaire Neuroticism scale â‰¥15/24

          -  Fluent in English language (in order to understand all study instructions and tasks
             using verbal stimuli)

        Exclusion Criteria:

          -  any significant medical condition

          -  current or past history of psychiatric disorder

          -  family history of mania

          -  pregnancy or breastfeeding

          -  taking any current medication (except the contraceptive pill)

          -  having taken part in other trials involving psychotropic drug intake in the previous
             three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Di Simplicio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford (at the time of study); MRC Cognition and Brain Sciences unit (current)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oxford, Department of Psychiatry, Warneford Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oxford</investigator_affiliation>
    <investigator_full_name>Martina Di Simplicio</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Neuroticism</keyword>
  <keyword>Emotion processing</keyword>
  <keyword>Eye gaze movements</keyword>
  <keyword>Heart Rate Variability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

